statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NGM Bio Announces Closing of Tender Offer

SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. ( NGM Bio ) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...

Financial Contrast: NGM Biopharmaceuticals (NASDAQ:NGM) and AgeX Therapeutics (NYSE:AGE)

AgeX Therapeutics (NYSE:AGE  Get Free Report) and NGM Biopharmaceuticals (NASDAQ:NGM  Get Free Report) are both small-cap medical companies, but which is the superior stock? We will...

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, HRT, NGM, SDPI

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, HRT, NGM, SDPI SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, HRT, NGM, SDPI PR Newswire NEW YORK, March 22, 2024 NEW YORK, March 22...

Kuehn Law Encourages NGM, CTLT, SDPI, and HRT Investors to Contact Law Firm

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek...

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates HRT, NGM

NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...

NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FREE, HRT, NGM, KNTE

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FREE, HRT, NGM, KNTE SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FREE, HRT, NGM, KNTE PR Newswire NEW YORK, March 18, 2024 NEW YORK, March 18...

NGM Biopharmaceuticals (NASDAQ:NGM) Rating Lowered to Market Perform at Raymond James

Raymond James cut shares of NGM Biopharmaceuticals (NASDAQ:NGM  Free Report) from an outperform rating to a market perform rating in a research note released on Tuesday, MarketBeat Ratings...

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates HRT, NGM, SCTL

NEW YORK, March 16, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates EGLE, X, PGTI, NGM

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates EGLE, X, PGTI, NGM SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates EGLE, X, PGTI, NGM PR Newswire NEW YORK, March 13, 2024 NEW YORK, March 13, 2024...

NGM Biopharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel biologic drug candidates. Its programs include NGM707 and pembrolizumab for treating metastatic solid tumors, Aldafermin for primary sclerosing cholangitis, and NGM120 for hyperemesis gravidarum. The company was founded by Jin Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.

Volume	2.39M
52-Wk High	$4.69
52-Wk Low	$0.6002

NGM Ngm Biopharmaceuticals Inc

About

Feed

News

Earnings

Fundamentals